This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A new intracellular drugdelivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drugdelivery technologies. Another key focus area will be the creation of a framework to develop advanced nano-delivery systems.
Sixfold Bioscience in partnership with Medicines Discovery Catapult, has been given the green light, through the award of an Innovate UK Smart Grant to test a pioneering system designed to deliver drugs directly to cancerous cells, without impacting the healthy cells around it.
Worldwide RNA Interference (RNAi) DrugDelivery Industry to 2025 – by Application, Technology and Region – ResearchAndMarkets.com Worldwide RNA Interference (RNAi) DrugDelivery Industry to 2025 – by Application, Technology and Region – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “RNA Interference (RNAi) (..)
SMi Group’s 13th Annual Conference: RNA Therapeutics 2022. Bolstering the latest advances and opportunities in RNA-based medicine. Delve into the latest innovations in novel RNAdelivery and target specificity. Engage in the growing advances and development of RNA tools for vaccines and anti-infectives. London, UK.
The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. RNA has the potential to underpin breakthrough treatments for a wide variety of diseases, including many cancers, and transform medicine as we know it.
In addition, NLCs offer benefits such as high drug loading capacity, improved drug retention and avoidance of drug expulsion. Advantages of Lipid Nanoparticle LNPs are gaining significant attention of formulation scientists in drugdelivery due to the various advantages offered by them.
RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.
XTALKS WEBINAR: DrugDelivery — Evaluating Off-The-Shelf and Novel DrugDelivery Solutions Live and On-Demand: Tuesday, July 11, 2023, at 1pm EDT (10am PDT) Register for this free webinar to learn about important tradeoffs when considering an off-the-shelf (OTS) drugdelivery platform vs. novel development.
Harness Safe & Efficacious Lipid-Based Delivery for Novel Therapeutics Beyond RNA & Hepatic Tissue. The recent success of the mRNA-LNP vaccines fueled biopharma to explore lipid-based nanoparticles for advanced drugdelivery.
Over time, various research studies have demonstrated the potential of exosomes ( membrane bound extracellular vesicles) in disease diagnosis, drugdelivery and therapeutic applications. In addition, they are involved in regulating the expression of the targets that are linked to RNA as they can affect the expression of RNA.
“Applying 3a’s proprietary enhanced RNA technology to PCR testing was a logical next step in our product development pipeline,” said Dr. Heinrich Jehle, managing director of 3a-Diagnostics. “We are currently developing two saliva-based tests to detect SARS-CoV-2 RNA. About XPhyto Therapeutics Corp.
One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.
Further, the biggest challenge in this domain is the purification which involve the use of hazardous solvents / materials and stability of drug products ( thereby, requiring specialized facilities and cold chain transportation).
Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. LNPs are spheric drugdelivery bodies which can be equipped with therapeutic payloads for intracellular delivery.
In the 20 th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. Our Social Media Platform. Web: [link]. LinkedIn: [link]. Twitter: [link]. Medium: [link]. Pinterest: [link].
In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drugdelivery agent. Cancer Immunotherapies : RNA molecules, such as siRNA, microRNA, and mRNA, have shown tremendous potential for immunomodulation and use as a cancer immunotherapy.
Over the last two decades the pharmaceutical industry has observed a paradigm shift from conventional drugdelivery strategies to more enhanced, potent, and targeted therapeutics. This led the researchers to find alternative pathways and drugdelivery strategies to enhance the potent delivery of the drug to the site of action.
Beam adds to drugdelivery stable with USD 120 Million GuideTx buy. The GuideTx technology screens for lipid nanoparticles inside the body that can be used to deliver RNA to cells throughout the body. Beam announced that it paid USD 120 million upfront to acquire Guide Therapeutics in an all-stock agreement.
“This marks another significant milestone as we continue to leverage our polypeptide nano-particle technology for siRNA drugdelivery to advance our pipeline of oncology therapeutic candidates,” said Patrick Lu , Ph.D., the founder, President and CEO of Sirnaomics. Chief Medical Officer. 1 and COX-2 gene expression.
While numerous cardiovascular drugdelivery devices and drug eluting stents are accessible for treating these conditions, treatment options for AF, including the anti-arrhythmic drugs, frequently prove ineffective.
Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. The next wave came from early research into liposomes and lipid nanoparticles, both of which are used for drugdelivery. Langer, now a David H.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content